NEW YORK (GenomeWeb News) – Saladax Biomedical today announced Ilex Medical will exclusively distribute three of its tests in Israel.
Under the agreement, Ilex will distribute My5-FU, MyPaclitaxel, and MyDocetaxel diagnostic reagent kits, which are designed to measure the level of the chemotherapy drugs in blood "to overcome the limitations associated with dosing based on body surface area," or BSA, Saladax said in a statement.
The tests are part of the Bethlehem, Penn.-based company's MyCare technology platform, which offers automated, rapid, robust, and cost-effective in vitro diagnostic tests for patient-specific chemotherapy dosing information for use by physicians.
"It is our goal to provide oncologists around the world with a new tool to offer their patients more effective chemotherapy treatment," Adrienne Choma, senior vice president and chief marketing officer of Saladax, said in a statement. "Our new MyCare technology optimizes chemotherapy drug doses to patients' individual needs, which is not achieved with BSA-based dosing."
Financial and other terms of the deal were not disclosed.
Ilex Medical is headquartered in Petach-Tikva, Israel and is part of the Ilex group. It focuses on in vitro diagnostic equipment, reagents, laboratory management software, blood bank diagnostic kits, and diagnostic support services for healthcare market in Israel.